scholarly journals Uremic Restless Legs Syndrome (RLS) and Sleep Quality in Patients With End-Stage Renal Disease on Hemodialysis: Potential Role of Homocysteine and Parathyroid Hormone

2013 ◽  
Vol 37 (4-5) ◽  
pp. 458-463 ◽  
Author(s):  
Katrin Gade ◽  
Sabine Blaschke ◽  
Andrea Rodenbeck ◽  
Andreas Becker ◽  
Heike Anderson-Schmidt ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
Sleep Quality ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Potential Role ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone

2019 ◽  
Vol 31 (3) ◽  
pp. 515-524
Author(s):  
T. T. Jansz ◽  
N. A. Goto ◽  
A. J. van Ballegooijen ◽  
H. C. Willems ◽  
M. C. Verhaar ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
Vertebral Fractures ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Clinical management of restless legs syndrome in end-stage renal disease patients

CNS Spectrums ◽  
2016 ◽  
Vol 22 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Zeyad T. Sahli ◽  
Jae Jo ◽  
Shaker A. Mousa ◽  
Frank I. Tarazi
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Treatment Guidelines ◽  
Small Sample ◽  
Limited Information ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Restless legs syndrome (RLS) is a common neurological movement disorder, characterized by restless and unpleasant sensations in the deep inside of legs. The symptoms of RLS are less noticeable during daytime, but more prevalent at night. Therefore, the disorder can induce low quality of life, insomnia, and impairment of daytime activity. RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality. The prevalence of RLS among dialysis patients is much higher compared to the prevalence of the same disorder in patients with normal renal functions. Even though there are recommended treatment guidelines for the general population established by Medical Advisory Board of the RLS foundation, which include the use of dopamine agonists, levodopa, gabapentin, benzodiazepines, and opioids, limited information is available on the effects of these therapies in ESRD patients. Since the existing clinical data were extrapolated from small sample sizes in short-term clinical trials, further clinical studies are still needed to better assess the efficacy, safety, and tolerability of these medications in patients with ESRD.

Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end-stage renal disease

2014 ◽  
Vol 22 (1) ◽  
pp. 142-149 ◽  
Author(s):  
C.-H. Lin ◽  
H.-N. Sy ◽  
H.-W. Chang ◽  
H.-H. Liou ◽  
C.-Y. Lin ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Restless Legs ◽  
Cerebrovascular Events ◽  
Stage Renal Disease ◽  
End Stage

Restless legs syndrome in end-stage renal disease: Clinical characteristics and associated comorbidities

2010 ◽  
Vol 11 (8) ◽  
pp. 785-790 ◽  
Author(s):  
Sonia Maria Holanda Almeida Araujo ◽  
Veralice Meireles Sales de Bruin ◽  
Lucas A. Nepomuceno ◽  
Marcos Lelio Maximo ◽  
Elizabeth de Francesco Daher ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Clinical Characteristics ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study

2021 ◽  
Vol 10 (3) ◽  
pp. e19-e19
Author(s):  
Natalia Stepanova ◽  
Ganna Tolstanova ◽  
Lesya Korol ◽  
Iryna Akulenko ◽  
Olena Savchenko ◽  
...  
Keyword(s):  
Pilot Study ◽  
Renal Disease ◽  
Healthy Volunteers ◽  
Effect Size ◽  
End Stage Renal Disease ◽  
Potential Role ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Introduction: End-stage renal disease (ESRD) patients have significant differences in plasma oxalic acid (POx) concentration under the same treatment conditions. Objectives: In the present study, we adopted the method of redoximetric titration with a KMnO4 solution to evaluate the effect of total fecal oxalate-degrading activity (ODA) on oxalate homeostasis in ESRD patients which has never been reported before. Patients and Methods: A total of 56 participants were enrolled in this cross-sectional pilot study, including 24 healthy volunteers (a control reference group) and 32 ESRD patients. Among the ESRD patients, there were 21 hemodialysis (HD) and 11 peritoneal dialysis (PD) patients. Total ODA in fecal samples as well as POx concentration, daily urinary oxalate (UOx) and PD effluent oxalate excretion were determined. Cohen’s d was computed to calculate the effect size using post-hoc analysis. Results: Total ODA in fecal microbiota ranged from -23 to 24%/0.01 g of feces and was statistically higher in healthy volunteers compared with the ESRD patients. The ESRD patients with positive total fecal ODA status had higher UOx excretion level and lower POx concentration compared with the patients with negative total fecal ODA status. Cohen’s d effect size was 1.99 and 1.05, respectively. Total fecal ODA was an independent risk factor associated with POx elevation in the ESRD patients. Conclusion: Our pilot study firstly demonstrated a potential role of total fecal ODA in oxalate homeostasis in ESRD patients. The results might be useful for determining sample size considerations and providing groundwork for future research projects.

Sign in / Sign up

Export Citation Format

Share Document